Failure to return pillbox is a predictor of being lost to follow-up among people living with HIV on antiretroviral therapy in rural Tanzania.


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
07 2022
Historique:
revised: 22 11 2021
received: 21 09 2021
accepted: 06 12 2021
pubmed: 30 12 2021
medline: 10 6 2022
entrez: 29 12 2021
Statut: ppublish

Résumé

Pill count is used to assess drug adherence in people living with HIV (PLHIV). Carrying a pillbox is associated with fear of concealment and stigma and might indicate poor adherence and predict someone who will be lost to follow-up (LTFU). We therefore assessed the association between pillbox return and being LTFU in rural Tanzania. This is a nested study of the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO). We included PLHIV aged ≥ 18 years enrolled in KIULARCO between January 2013 and March 2019 with follow-up through January 2020, who were on antiretroviral treatment (ART) for ≥ 6 months. Baseline was defined as the latest ART initiation or KIULARCO enrolment. We determined the association between time-dependent failed pillbox return updated at every visit and LTFU using Kaplan-Meier estimation and Cox models. Among 2552 PLHIV included in the study, 1735 (68.0%) were female, 959 (40.3%) had a WHO stage III/IV and 1487 (66.4%) had a CD4 cell count < 350 cells/µL. The median age was 38.4 years [interquartile range (IQR): 31.7-46.2]. During a median follow-up of 33.1 months (IQR: 17.5-52.4), 909 (35.6%) participants were LTFU, 43 (1.7%) died and 194 (7.6%) had transferred to another clinic. The probability of being LTFU was higher among PLHIV with failed pillbox return than among those who returned their pillbox [30.0%, 95% confidence interval (CI): 26.8-33.2% vs. 19.4%, 95% CI: 17.4-21.6%, respectively, at 24 months (hazard ratio = 1.67, 95% CI: 1.46-1.90; p < 0.001)]. Failed pillbox return was associated with a higher risk of being LTFU and could be used as a simple tool to identify PLHIV for appropriate interventions to reduce their chance of being LTFU.

Identifiants

pubmed: 34964236
doi: 10.1111/hiv.13223
pmc: PMC9306592
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-672

Investigateurs

Aschola Asantiel (A)
Farida Bani (F)
Manuel Battegay (M)
Theonestina Byakuzana (T)
Adolphina Chale (A)
Francisca Chuwa (F)
Anna Eichenberger (A)
Gideon Francis (G)
Hansjakob Furrer (H)
Tracy R Glass (TR)
Speciosa Hwaya (S)
Aneth V Kalinjuma (AV)
Bryson Kasuga (B)
Andrew Katende (A)
Namvua Kimera (N)
Bernard Kivuma (B)
Yassin Kisunga (Y)
Olivia Kitau (O)
Thomas Klimkait (T)
Ezekiel Luoga (E)
Herry Mapesi (H)
Mengi Mkulila (M)
Julius Mkumbo (J)
Margareth Mkusa (M)
Slyakus Mlembe (S)
Dorcas K Mnzava (DK)
Gertrud J Mollel (GJ)
Lilian Moshi (L)
Germana Mossad (G)
Dolores Mpundunga (D)
Athumani Mtandanguo (A)
Selerine Myeya (S)
Sanula Nahota (S)
Regina Ndaki (R)
Robert C Ndege (RC)
Agatha Ngulukila (A)
Amina Nyuri (A)
James Okuma (J)
Daniel H Paris (DH)
Aloyce Sambuta (A)
Leila Samson (L)
Elizabeth Senkoro (E)
George Sikalengo (G)
Jenifa Tarimo (J)
Yvan Temba (Y)
Juerg Utzinger (J)
Fiona Vanobberghen (F)
John Wigay (J)
Herieth Wilson (H)

Informations de copyright

© 2021 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

Références

BMJ Glob Health. 2016 Sep 15;1(2):e000010
pubmed: 28588933
Swiss Med Wkly. 2017 Jul 11;147:w14485
pubmed: 28695551
AIDS Behav. 2020 Jan;24(1):142-150
pubmed: 30927114
SSM Popul Health. 2018 Nov 15;7:007-7
pubmed: 30560196
Clin Ther. 2007 Apr;29(4):711-6
pubmed: 17617294
Am J Epidemiol. 2010 Apr 15;171(8):924-31
pubmed: 20219765
BMC Infect Dis. 2020 Jun 22;20(1):439
pubmed: 32571232
BMC Health Serv Res. 2019 Sep 4;19(1):628
pubmed: 31484571
Int J Methods Psychiatr Res. 2002;11(2):68-74
pubmed: 12459796
PLoS One. 2017 Jul 18;12(7):e0180983
pubmed: 28719610
Sex Transm Infect. 2010 Dec;86 Suppl 2:ii67-71
pubmed: 21106518
Ann Intern Med. 2000 Jul 4;133(1):21-30
pubmed: 10877736
BMC Infect Dis. 2015 Nov 14;15:520
pubmed: 26573923
AIDS Care. 2011 Mar;23(3):378-82
pubmed: 21347901
AIDS Res Treat. 2016;2016:7925052
pubmed: 27110395
PLoS One. 2019 Mar 21;14(3):e0214014
pubmed: 30897131
HIV Clin Trials. 2000 Jul-Aug;1(1):36-46
pubmed: 11590488
Lancet HIV. 2016 Dec;3(12):e554-e555
pubmed: 27771232
Eur J Cardiovasc Nurs. 2003 Dec;2(4):323
pubmed: 14667488
AIDS Care. 2000 Jun;12(3):255-66
pubmed: 10928201
HIV Med. 2022 Jul;23(6):661-672
pubmed: 34964236
AIDS Behav. 2017 Sep;21(9):2579-2588
pubmed: 28058565
AIDS Res Hum Retroviruses. 2010 Jun;26(6):685-91
pubmed: 20518649
Clin Infect Dis. 2005 Jan 1;40(1):158-63
pubmed: 15614706
N Am J Med Sci. 2014 Sep;6(9):453-9
pubmed: 25317390
Ann Intern Med. 2012 Jun 5;156(11):817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291,
pubmed: 22393036
AIDS Behav. 2018 May;22(5):1671-1678
pubmed: 28185021
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):542-545
pubmed: 26990822
PLoS One. 2019 Jul 25;14(7):e0219903
pubmed: 31344057
J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11
pubmed: 19745753
Patient Prefer Adherence. 2020 Jan 23;14:153-161
pubmed: 32021125
BMC Public Health. 2020 Mar 14;20(1):328
pubmed: 32171279
J Int AIDS Soc. 2020 Mar;23(3):e25460
pubmed: 32128998
Am J Epidemiol. 2014 Dec 15;180(12):1208-12
pubmed: 25399412
Am J Epidemiol. 2021 Feb 1;190(2):251-264
pubmed: 33524120

Auteurs

Robert C Ndege (RC)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.
St. Francis Referral Hospital, Ifakara, Tanzania.

James Okuma (J)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Aneth V Kalinjuma (AV)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.
School of Public Health, Faculty of Health Sciences, Department of Epidemiology and Biostatistics, University of the Witwatersrand, Johannesburg, South Africa.

Julius Mkumbo (J)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.

Elizabeth Senkoro (E)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.
St. Francis Referral Hospital, Ifakara, Tanzania.

Gideon Fue (G)

St. Francis Referral Hospital, Ifakara, Tanzania.

Leila Samson (L)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.

Herry Mapesi (H)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.
Swiss Tropical and Public Health Institute, Basel, Switzerland.

Siraji Shabani (S)

Ministry of Health, National AIDS Control Program, Dar es Salaam, Tanzania.

Tracy R Glass (TR)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Manuel Battegay (M)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

Daniel H Paris (DH)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Fiona Vanobberghen (F)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Maja Weisser (M)

Ifakara Health Institute, Ifakara Branch, Ifakara, Tanzania.
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH